1. Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel- group trial 
Hood Thabit, PhD, Sara Hartnell, BSc, Janet M Allen, RN, Andrea Lake, DipHE, Malgorzata E Wilinska, PhD, Yue Ruan, MEng, Mark L Evans, MD, Anthony P Coll, PhD, Dr Roman Hovorka, PhD 
The Lancet Diabetes & Endocrinology 
Volume 5, Issue 2, Pages (February 2017)
DOI: /S (16)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

2. Figure 1
Trial profile
The Lancet Diabetes & Endocrinology 2017 5, DOI: ( /S (16) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

3. Figure 2 Median sensor glucose concentration and insulin delivery
(A) Median (IQR) sensor glucose concentration during closed-loop insulin delivery (the solid red line and the red shaded area) and control interventions (the dashed black line and the grey shaded area) from 0000 h to 0000 h. The lower and upper limits of the target glucose concentration range of 5·6–10·0 mmol/L are denoted by the horizontal dashed lines. (B) Median (IQR) algorithm-directed insulin delivery during the closed-loop intervention.
The Lancet Diabetes & Endocrinology 2017 5, DOI: ( /S (16) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

4. Figure 3
Participant responses to the questionnaire about closed-loop insulin delivery
The Lancet Diabetes & Endocrinology 2017 5, DOI: ( /S (16) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions